Brief: Armata Pharmaceuticals Announces Clearance Of Investigational New Drug Application To Initiate Phase 1B/2A Clinical Trial Of Lead Candidate AP-Pa02 In Pseudomonas Aeruginosa Infections
15/10/2020 12:51
Oct 15 (Reuters) - Armata Pharmaceuticals Inc ARMP.A :
* ARMATA PHARMACEUTICALS ANNOUNCES CLEARANCE OF
INVESTIGATIONAL
NEW DRUG (IND) APPLICATION TO INITIATE PHASE 1B/2A CLINICAL
TRIAL OF LEAD CANDIDATE AP-PA02 IN PSEUDOMONAS AERUGINOSA
INFECTIONS
* ARMATA PHARMACEUTICALS INC - EXPECTS TO INITIATE SAD
COHORT BY
END OF 2020
Source text for Eikon: ID:nPn9SNV4da
Further company coverage: ARMP.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles